Skip to content

COMPARATIVE EFFICACY OF 200 UNITS VERSUS 155 UNITS OF ONABOTULINUMTOXIN A FOR CHRONIC MIGRAINE.

2026 · Georgian medical news · Vol 376-377, pp. 381-388 · 0 citations
Medicine

TL;DR

The study concludes that administering 200 U of OnaBT-A, significantly decreases the frequency and duration of headaches when compared to 155 U, and recommends considering this dosage for patients who do not accomplish adequate relief with 155 U of OnaBT-A.

View source

Similar papers

Open access Oct 2026

Onabotulinum Toxin A (BoNTA) in the Treatment of Chronic and High-Frequency Episodic Migraine: A Real-World Study

In this retrospective uncontrolled cohort, reductions in headache frequency and other clinical improvements were observed during BoNTA treatment in patients with CM and HFEM, and these findings cannot establish the efficacy of BoNTA in HFEM.

F. Jiménez-Jiménez, Alba Cárcamo-Fonfría, Silvina Espada-Rubio et al. · 0 citations
Open access Sep 2026

Comparative effectiveness and safety of topiramate versus amitriptyline for the prophylactic management of chronic migraine: a prospective comparative study

Background Chronic migraine is a chronic disabling neurological disease and has a significant impact on quality of life. Topiramate and amitriptyline are commonly used for migraine prevention, but treatment decisions should consider their effectiveness and safety profiles. This study aimed to compare the effectiveness...

M. Karami, Amber Hassan, Amal M. Alkhotani et al. · 0 citations
Open access Nov 2026

P044 | COMBINATION THERAPY WITH ATOGEPANT AND ONABOTULINUMTOXINA IN CHRONIC MIGRAINE: PRELIMINARY REAL-WORLD EVIDENCE FROM AN ONGOING STUDY

Background. Chronic migraine (CM) is a highly disabling neurological disorder associated with substantial functional impairment and healthcare burden. Preventive therapies targeting calcitonin gene-related peptide (CGRP) pathways and onabotulinumtoxinA have demonstrated efficacy in CM management. This ongoing real-worl...

Unknown authors · 0 citations
Open access Nov 2026

OC07 | LONG-TERM COMBINATION WITH ONABOTULINUMTOXINA AND ATOGEPANT TO ACHIEVE HIGHER STANDARDS OF MIGRAINE CONTROL: A 52-WEEK, PROSPECTIVE, REAL-WORLD EVALUATION (SYNERGY STUDY)

Background. Patients with chronic migraine (CM) who remain inadequately controlled despite ongoing preventive monotherapy represent a particularly challenging population. Whether the clinical benefit achieved after adding a second preventive therapy can be maintained over the long term remains poorly understood. Herein...

Unknown authors · 0 citations
Open access Nov 2026

P020 | ATOGEPANT AS ADD-ON THERAPY TO ONABOTULINUMTOXINA IN CHRONIC MIGRAINE: A REAL-WORLD STUDY

Background. OnabotulinumtoxinA (BoNT-A) is a well-established preventive treatment for chronic migraine (CM). Given the high burden of CM, many patients require additional preventive therapy for adequate disease control. Although BoNT-A plus anti-CGRP treatments may provide synergistic benefits, real-world evidence rem...

Unknown authors · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.